论文部分内容阅读
目的:观察前列地尔注射液对重型肝炎的治疗效果。方法:选取2013年6月-2014年6月我院收治的重型肝炎患者100例,随机将患者分为观察组与对照组,每组各50例。对照组患者以常规方法进行治疗;而观察组患者在对照组基础上联合前列地尔注射液治疗,对两组患者的治疗效果进行分析。结果:观察组患者的治疗总有效率为74%,对照组为42%,组间比较,差异具有统计学意义(P<0.05);两组患者在治疗前的凝血酶原活动度(PTA)、总胆红素(TBIL)、谷丙转氨酶(ALT)等指标比较,差异无统计学意义(P>0.05);而治疗后,两组患者的TBIL与ALT指标均下降,PTA指标上升,组间比较,差异具有统计学意义(P<0.05)。结论:在常规治疗基础上联合前列地尔注射液治疗重型肝炎临床效果显著,可有效改善患者的肝功能,且安全性较高。
Objective: To observe the therapeutic effect of alprostadil injection on severe hepatitis. Methods: 100 patients with severe hepatitis treated in our hospital from June 2013 to June 2014 were randomly divided into observation group and control group, with 50 cases in each group. Patients in the control group were treated by the conventional method. Patients in the observation group were treated with alprostadil injection on the basis of the control group, and the therapeutic effects of the two groups were analyzed. Results: The total effective rate was 74% in the observation group and 42% in the control group. There was a significant difference between the two groups (P <0.05). The activity of prothrombin (PTA) (P> 0.05). After treatment, the TBIL and ALT indexes decreased and the PTA index increased in both groups, and the levels of TBI, ALT and ALT in the two groups were not significantly different Between the two groups, the difference was statistically significant (P <0.05). Conclusion: The combination of alprostadil and conventional alprostadil in the treatment of severe hepatitis has significant clinical effect, which can effectively improve the liver function of patients with high safety.